GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK said its experimental chronic hepatitis B drug achieved a functional cure in nearly 20% of patients in late-stage studies, a meaningful clinical step toward a finite treatment course. The result supports the drug's commercial potential versus lifelong antiviral pills and is a positive development for GSK's pipeline. Market impact is likely company-specific rather than sector-wide.

Analysis

GSK said its experimental chronic hepatitis B drug achieved a functional cure in nearly 20% of patients in late-stage studies, a meaningful clinical step toward a finite treatment course. The result supports the drug's commercial potential versus lifelong antiviral pills and is a positive development for GSK's pipeline. Market impact is likely company-specific rather than sector-wide.